Approval

Sovleplenib wins dual China approval

China's NMPA approved HUTCHMED's oral Syk inhibitor sovleplenib for previously treated adults with primary chronic immune thrombocytopenia or warm autoimmune hemolytic anemia. In the phase 3 ESLIM-01 study, sustained platelet response was 48.4% with sovleplenib versus 0% with placebo; long-term findings also showed durable responses. In phase 3 ESLIM-02, sustained response was 66% with sovleplenib versus 15% with placebo, with fewer patients requiring emergency treatment.

Written by Gosset from public sources. Source types: Press release · SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call